PRAME and adenocarcinoma: PRAME was broadly expressed across cutaneous melanoma (Fig. 2a) and lung tumors (Fig. S2) with distinct TMB and PD-L1 biomarker profiles, with some enrichment in NSCLC adenocarcinomas with higher TMB and lower PD-L1 levels (Fig. S2a).